Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | TACR2 | P21452 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.38 |
| ▸ | TST | Q16762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987593 | 1.00 | ESR1 (0.38) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL1286045 | 1.00 | ESR1 (0.38) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL27868029 | 1.00 | ESR1 (0.38) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL1285757 | 1.00 | ESR1 (0.38) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL16892538 | 1.00 | ESR1 (0.38) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| Magnesium Chloride Anhydrous SCHEMBL28886869 | 0.93 | HTR2A (0.38) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL3380 | 0.92 | — | — | |
| SCHEMBL16892561 | 0.86 | SIGMAR1 (0.47) | ALDH1A1LMNA | |
| SCHEMBL16892539 | 0.86 | SIGMAR1 (0.47) | ALDH1A1LMNA | |
| SCHEMBL16892552 | 0.86 | ESR1 (0.36) | ESR1TP53HSD17B10ACHEGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117615586-A | Organic solar cell active layer based on liquid crystal molecules and application thereof | 江西师范大学 | 2024-02-27 | — | — | CN | claimed |
| CN-117202682-A | Composite tin-based perovskite film and preparation method and application thereof | 极电光能有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-111154075-B | Fluoroquinoxaline-thiophene copolymer and preparation method thereof | 天津理工大学 | 2022-09-30 | — | — | CN | claimed |
| CN-114672003-A | Conjugated polymer based on thiophene [3,4-c ] pyrrole-4, 6-diketone structure and preparation method and application thereof | 天津理工大学 | 2022-06-28 | — | — | CN | claimed |
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | claimed |
| CN-109705137-B | Doping-free hole transport material based on dithieno [3,2-b:2',3' -d ] pyrrole and synthetic method | 南京理工大学 | 2021-05-04 | — | — | CN | claimed |
| CN-111154075-A | Fluoroquinoxaline-thiophene copolymer and preparation method thereof | 天津理工大学 | 2020-05-15 | — | — | CN | claimed |
| US-20110087034-A1 | Organic Semiconductor Material | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2011-04-14 | — | — | US | claimed |
| EP-2248818-A1 | ORGANIC SEMICONDUCTOR MATERIAL | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | claimed |
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | claimed |
| US-6627624-B1 | Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, | NEUROGEN CORPORATION | 2003-09-30 | — | — | US | claimed |
| EP-3902023-B1 | COMPOSITION CONTAINING ORGANIC SEMICONDUCTOR, SOLUTION FOR FORMING ORGANIC SEMICONDUCTOR LAYER, ORGANIC SEMICONDUCTOR LAYER, AND ORGANIC THIN FILM TRANSISTOR | TOSOH CORP (JP) | 2024-04-24 | — | — | EP | disclosed |
| CN-117615586-A | Organic solar cell active layer based on liquid crystal molecules and application thereof | 江西师范大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-117304233-A | Iridium metal complex, application thereof and organic electroluminescent device | 清华大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-117202682-A | Composite tin-based perovskite film and preparation method and application thereof | 极电光能有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-6627624-B1 | Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, | NEUROGEN CORPORATION | 2003-09-30 | — | — | US | disclosed |
| US-6380210-B1 | USEFUL IN DIAGNOSIS AND TREATMENT OF ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS, DEPRESSION, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND ENHANCEMENT OF MEMORY AND ALERTNESS | NEUROGEN CORPORATION | 2002-04-30 | — | — | US | disclosed |
| EP-0035228-B1 | TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| US-4372953-A | Tetrazole derivatives, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-02-08 | — | — | US | disclosed |
| EP-0035228-A1 | Tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087034-A1 | Organic Semiconductor Material | OR10J3, TST, OR51E2 | ESR1 1107/4885ADRA2A 2494/4885ADORA3 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.